FDA Reopens Pre-Submissions For Non-COVID-19 Products
Executive Summary
The US agency now has the staff it needs to review pre-submissions for devices that aren’t related to the pandemic, says a new blog post from device center director Jeff Shuren and Office of Product Evaluation and Quality director William Maisel.
You may also be interested in...
EUA Draft Guidance: FDA Wants ‘Transition Implementation Plan’ Along With Marketing Submission
In a long-awaited draft guidance document, the US agency lays bare its thinking on how companies can best ensure that their products granted emergency use authorization status can still be sold post-pandemic (or not).
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Implant
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.